

Protea Fund - Sectoral Biotech Opportunities Fund IF EUR / LU1176837026 / A14NHD / FundPartner Sol.(EU)

Last 10/01/2024 ¹	Region	Branch	Type of yield	Type
10.14 EUR	Worldwide	Sector Biotechnology	reinvestment	Equity Fund



Risk key figures

SRI	1	2	3	4	5	6	7
Mountain-View Funds Rating ²	EDA ³						
	75						

Yearly Performance

2023	+0.82%
2022	-7.60%
2021	+0.77%
2020	+18.75%
2019	+16.40%

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	2.00%	Minimum investment	EUR 250,000.00
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Biotechnology	Deposit fees	0.00%	UCITS / OGAW	Yes
Fund domicile	Luxembourg	Redemption charge	0.00%	Performance fee	0.00%
Tranch volume	(10/01/2024) USD 2.24 mill.	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(10/01/2024) USD 27.18 mill.	Dividends		Investment company	
Launch date	2/27/2015	FundPartner Sol.(EU)			
KESt report funds	Yes	15A, avenue J. F. Kennedy, 1855, Luxembourg			
Business year start	01.07.	Luxembourg			
Sustainability type	-	www.group.pictet/de			
Fund manager	-				

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	-2.41%	+4.32%	+3.36%	+9.39%	+5.30%	-9.79%	+43.02%	+1.40%
Performance p.a.	-	-	-	+9.39%	+2.62%	-3.37%	+7.41%	+0.14%
Sharpe ratio	-1.99	0.34	0.08	0.35	-0.04	-0.31	0.17	-0.12
Volatility	15.28%	16.49%	16.36%	17.41%	17.08%	21.29%	24.81%	25.70%
Worst month	-	-6.14%	-6.14%	-6.14%	-6.71%	-12.25%	-12.25%	-14.95%
Best month	-	5.31%	11.60%	11.60%	11.60%	11.60%	15.32%	15.32%
Maximum loss	-5.14%	-6.87%	-10.66%	-10.66%	-18.60%	-32.99%	-34.93%	-

Distribution permission

Austria, Germany, Switzerland

1 Important note on update status: The displayed date refers exclusively to the calculation of the NAV.

2 The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

3 Displays the Ethical-Dynamical Ratio calculated according to standard criteria. The maximum value is 100. For more information visit [EDA](#)

Protea Fund - Sectoral Biotech Opportunities Fund IF EUR / LU1176837026 / A14NHD / FundPartner Sol.(EU)

Investment strategy


While respecting the principle of risk diversification, the Sub-Fund's net assets are primarily invested in equities and equity-related securities (such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs), European Depositary Receipts (EDRs)) issued by innovative small, mid and large cap biotech companies which are active in the human medicine sector. While no geographical restrictions apply, the Sub-Fund's investments are centered in North America and Western Europe. The Sub-Fund may invest in transferable securities and money market instruments from new issues to benefit from particularly innovative projects in the healthcare sector, in particular in innovative projects in the drugs sector. Up to 10% of the Sub Fund's net assets may be invested in Special Purpose Acquisition Companies. The Sub-Fund may invest up to 33% of its net assets, via Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect, in China A-Shares. Up to 33% of the Sub-Fund's net assets may be invested outside the aforementioned investment universe including, but not limited to equities of issuers of other business segments than biotech, in fixed and variable interest securities. The Sub-Fund may not invest more than 10% of its net assets in other UCIs or UCITS.

Investment goal


This Sub-Fund invests primarily in innovative biotech companies developing novel drugs in therapeutic areas with large unmet medical needs. Investments are made across all market caps, with significant exposure to mid- and small-cap biotech companies, due to their high degree of innovation. Novel and differentiated treatments benefit from a favorable regulatory and commercial environment, with the potential for shortened development timelines, rapid market adoption as well as strong pricing and operating margins. Innovation in biotech has created large new markets, and tremendous commercial potential remains in many diseases and novel therapeutic modalities, such as mRNA and gene therapy.

Assessment Structure


Assets




Largest positions



Countries



Branches



Currencies

